Showing results (1871-1880 of 1,955) with videos related to
Sort By:
Pageof 196
Nature|January 28, 2021
AIM2 in regulatory T cells restrains autoimmune diseasesWei-Chun Chou, Zengli Guo, Hao Guo, et al.Scientific Data|November 7, 2018
Enabling precision medicine in neonatology, an integrated repository for preterm birth researchMarina Sirota, Cristel G Thomas, Rebecca Liu, et al.Cancer Medicine|August 22, 2025
A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015Wenting Gan, Weina Zhang, Jiaoyang Cai, et al.Nature Medicine|January 31, 2012
A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapyGe Zhang, Baosheng Guo, Heng Wu, et al.Proceedings of the National Academy of Sciences of the United States of America|May 26, 2026
Atomic layer-deposited nucleation layers to control zinc morphology and suppress hydrogen evolutionAjay Ravi, Sanzeeda Baig Shuchi, Guangxia Feng, et al.Bioorganic & Medicinal Chemistry Letters|May 21, 2013
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonistsGuohua Zhao, Chet Kwon, Sharon N Bisaha, et al.Arthritis and Rheumatism|July 13, 2004
Genetic studies in familial ankylosing spondylitis susceptibilityGe Zhang, Jingchun Luo, Jane Bruckel, et al.Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.Oncotarget|May 10, 2015
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapyHui Xu, Shervin Rahimpour, Cody L Nesvick, et al.Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.Pageof 196